INTERNATIONAL PHARMACEUTICAL INDUSTRY
Innovators and generics manufacturers are expanding their established portfolio across all markets – both mature and emerging ones. In fact, emerging markets offer many new opportunities with their spending power and potential for high volumes. These markets are very price-sensitive and have led to greater penetration of established products with both branded and generic versions. Strategic partnerships can serve as an essential enabler of this expansion. In this new business model
which involves creating and fostering synergistic partnerships across multiple stakeholders, data exchange agreements and data hand-offs increase operational complexities and may result in enhanced exposure to safety and regulatory risks. All potential gaps in safety monitoring need to be managed proactively.
Read the full article.Proactive Safety Management – IPI Winter 2013